(S)-1-苄基-5-氧代吡咯烷-2-羧酸 | 78964-11-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-1-苄基-5-氧代吡咯烷-2-羧酸
• 英文名称: 1-benzyl-5-oxopyrrolidine-2-carboxylic acid
• 英文别名: N-benzylpyroglutamic acid；(+/-)-5-oxo-1-(phenylmethyl)proline；N-Benzylpyroglutaminsaeure
• CAS: 78964-11-1
• 化学式: C₁₂H₁₃NO₃
• 分子量: 219.24
• InChiKey: MOHLVDJRXGVGOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-1-苄基-5-氧代吡咯烷-2-羧酸 在 三氯化铝 吡啶 、 氯化亚砜 、 苄基三甲基氢氧化铵 作用下， 以 甲醇 、 苯 为溶剂， 反应 2.91h， 生成 10a-cyanoethyl-1,2,3,5,10,10a-hexahydrobenzindolizine-3,10-dione
  参考文献：
  名称：

  Rigo, Benoit; Kolocouris, Nicolas, Journal of Heterocyclic Chemistry, 1983, vol. 20, p. 893 - 898

  摘要：

  DOI：
• 作为产物：
  描述：

  5-氧代吡咯烷-2-羧酸乙酯 在 sodium hydride 、 sodium hydroxide 作用下， 以 苯 为溶剂， 反应 25.5h， 生成 (S)-1-苄基-5-氧代吡咯烷-2-羧酸
  参考文献：
  名称：

  Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: Preliminary results on the role of electronic characteristics for affinity and function

  摘要：

  17-Cyclopropylmethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 alpha-(isoquinoline-3'-carboxamido)morphinan (NAQ) was previously designed following the 'message-address' concept and was identified as a potent and highly selective mu opioid receptor (MOR) ligand based on its pharmacological profile. We here report the preliminary structure activity relationship (SAR) studies of this novel lead compound. For the new ligands synthesized as NAQ analogues, their binding assay results showed that a longer spacer and a saturated ring system of the side chain were unfavorable for their MOR selectivity over the kappa and delta opioid receptors. In contrast, substitutions with different electronic properties at either 1'- or 4'-position of the isoquinoline ring of the side chain were generally acceptable for reasonable MOR selectivity. The majority of NAQanalogues retained low efficacy at the MOR compared to NAQin the S-35-GTP[gamma S] binding assays while electron-withdrawing groups at 1'-position of the isoquinoline ring induced higher MOR stimulation than electron-donating groups did. In summary, the electronic characteristics of substituents at 1'- or 4'-position of the isoquinoline ring in NAQ seem to be critical and need to be further tuned up to achieve higher MOR selectivity and lower MOR stimulation. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.07.043

文献信息

• Novel amides useful for treating pain
  申请人：Zheng Zhu Guo

  公开号：US20050009841A1

  公开（公告）日：2005-01-13

  The present invention relates to compounds of formula (I) that useful in treating pain.

  本发明涉及一种用于治疗疼痛的化合物，其化学式为（I）。
• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20030144175A1

  公开（公告）日：2003-07-31

  The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了4-氨基-氮杂七环-3-酮蛋白酶抑制剂及其药用可接受的盐、水合物和溶剂化物，其抑制蛋白酶，包括卡特普辛K，这些化合物的药物组合物，这些化合物的新中间体，以及治疗骨骼过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说，是骨关节炎和类风湿关节炎；帕吉特病；恶性高钙血症；和代谢性骨病，包括通过向需要的患者施用本发明化合物来抑制骨质流失或过度软骨或基质降解。
• [EN] 3,7-DIAZABICYCLO[3.3.1 ]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS<br/>[FR] CARBOXAMIDES DE 3,7-DIAZABICYCLO[3.3.1]NONANE À TITRE D'AGENTS ANTITHROMBOTIQUES
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2015044951A1

  公开（公告）日：2015-04-02

  The present invention relates to the 3,7-diazabicyclo[3.3.1]nonane carboxamides and process for preparation thereof. The present invention further relates to the compounds of general formula (1) possessing anti-thrombotic (anti-platelet) activities. The invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors both in vitro and in vivo. Further, invention also relates these class of compounds exhibiting anti-platelet efficacy through dual mechanism inhibited both collagen as well as U46619 (thromboxane receptor agonist) induced platelet aggregation. General formula (1) Wherein, R' is; wherein R is selected from alkyl, acyl, tosyl, tert-butyloxycarbonyl, araalkyl or substituted araalkyl groups; R'' is selected preferably from halogen, cyano, lower alkyl, aryl, substituted aryl, and tosyl groups; R1 is selected from hydrogen and lower alkyl groups; R2 is selected from lower alkyl and aryl groups; R3 is selected from tert-butyloxycarbonyl and bezyloxycarbonyl groups; n = 0,1.

  本发明涉及3,7-二氮杂双环[3.3.1]壬烷羧酰胺及其制备方法。本发明还涉及具有抗血栓（抗血小板）活性的一般式（1）化合物。该发明还涉及将这些基团用作体外和体内介导的胶原受体抑制剂，抑制胶原诱导的血小板粘附和聚集。此外，该发明还涉及这类化合物通过双重机制表现出抗血小板功效，既抑制了胶原又抑制了U46619（血栓素受体激动剂）诱导的血小板聚集。一般式（1）中，其中，R'为；其中R选自烷基、酰基、对甲苯磺酰基、叔丁氧羰基、芳基烷基或取代芳基烷基；R''优选选自卤素、氰基、低烷基、芳基、取代芳基和对甲苯磺基；R1选自氢和低烷基；R2选自低烷基和芳基；R3选自叔丁氧羰基和苯甲氧羰基；n = 0,1。
• [EN] HYDRAZIDE DERIVATIVES AND THEIR SPECIFIC USE AS ANTIBACTERIAL AGENTS BY CONTROLLING ACINETOBACTER BAUMANNII BACTERIUM<br/>[FR] DÉRIVÉS D'HYDRAZIDE ET LEUR UTILISATION SPÉCIFIQUE EN TANT QU'AGENTS ANTIBACTÉRIENS POUR LUTTER CONTRE UNE BACTÉRIE ACINETOBACTER BAUMANNII
  申请人：YNCREA HAUTS DE FRANCE

  公开号：WO2020169682A1

  公开（公告）日：2020-08-27

  The present invention relates to compounds of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, their use as a drug, in particular as antibacterial agent, notablyforpreventingand/or treating disorders associated to Acinetobacter baumannii. The present invention also relates to pharmaceutical compositions containing said compoundsand the process for preparing said compounds.

  本发明涉及以下一般式（I）的化合物，或其药学上可接受的盐和/或溶剂，其用作药物，特别是作为抗菌剂，尤其用于预防和/或治疗与鲍曼不动杆菌相关的疾病。本发明还涉及含有上述化合物的药物组合物以及制备上述化合物的方法。
• Novel Receptor Antagonists and Their Methods of Use
  申请人：Chambers J. Laura

  公开号：US20080009541A1

  公开（公告）日：2008-01-10

  The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.

  本发明涉及一种新型的氧代脯氨酰胺衍生物，其化学式为（I），可以调节P2X7受体功能，并能够拮抗P2X7受体上ATP的作用，以及利用这些化合物或其药物组合物治疗由P2X7受体介导的疾病，例如疼痛、炎症和神经退行性疾病。